bims-micgli Biomed News
on Microglia
Issue of 2026–01–04
twenty papers selected by
Matheus Garcia Fragas, Universidade de São Paulo



  1. J Neurochem. 2025 Dec;169(12): e70335
      Cerebral amyloid angiopathy (CAA) shares amyloid-β (Aβ) deposition as a pathological hallmark with the extracellular plaques of Alzheimer's disease (AD). While both disease processes involve progressive, decades-long deposition of fibrillar Aβ peptide, they differ in isoform composition. We hypothesized that post-translational modifications (PTMs) on Aβ would also differ between CAA and parenchymal plaques. Using Lys-N enzymatic digestion followed by quantitative mass spectrometry, we profiled Aβ isoforms and N-terminus PTMs (aspartic acid isomerization and pyroglutamate formation) across CAA severity and compared them to parenchymal plaque Aβ in AD. Moderate to severe CAA were dominated by intact N-terminus (Aβ1-x ~ 95%) with minimal N-truncated species (Aβ2-x, Aβ3pGlu-x, and Aβ4-x), whereas parenchymal plaques displayed diverse N-terminus truncations and PTMs. Increasing CAA severity correlated with a shift from longer, hydrophobic C-terminal isoforms (Aβ41, Aβ42, and Aβ43) to shorter, less hydrophobic C-terminal isoforms (Aβ37, Aβ38, Aβ39, and Aβ40). Importantly, moderate and severe CAA displayed minimal isomerization of Asp1 and Asp7 residues. These patterns suggest distinct Aβ aggregation mechanisms in CAA versus parenchymal plaques. We propose that the intact and unmodified N-terminus found in CAA is due to its inclusion within the protofibril structure making them less disordered and inaccessible to post-translational modifications, in contrast to plaque-associated Aβ. These biochemical differences may reflect underlying structural distinctions in protofibril architectures, with potential implications for biomarker development for early CAA detection and therapeutic targeting of vascular versus parenchymal Aβ.
    Keywords:  Alzheimer's disease; amyloid‐β; cerebral amyloid angiopathy; mass spectrometry; parenchymal plaques
    DOI:  https://doi.org/10.1111/jnc.70335
  2. J Neurochem. 2026 Jan;170(1): e70341
      Microglia are the main innate immune cells residing in the brain parenchyma. Their activation and resulting neuroinflammation have emerged as major pathogenic mechanisms in neurodegenerative disorders, particularly in Alzheimer's disease (AD). The accumulation of amyloid-β oligomers (AβOs) and microglia activation play crucial roles in the pathogenesis of AD. In a second vein, the development of innate immune memory in response to different stimuli is a vital mechanism that enables microglia to adjust their response to subsequent inflammatory challenges. While there is increasing evidence that repeated bouts of peripheral inflammation lead to training or tolerance in microglia, the impact of tolerance on the inflammatory response induced by AβOs remains to be determined. In this study, we investigated whether lipopolysaccharide (LPS)-induced tolerance affects microglial responses to AβOs. For that, organotypic hippocampal cultures were repeatedly challenged with LPS before being exposed to AβOs. We measured cytokine levels and evaluated changes in microglial activation and morphology following exposure of cultures to AβOs. A significant decrease in cytokine production was observed when hippocampal slice cultures were repeatedly challenged with LPS. Interestingly, microglial activation and the resulting inflammatory response induced by AβOs were prevented when these cultures had been previously challenged with LPS. Moreover, the changes in microglial morphology and cytokine production resulting from repeated LPS stimulation were associated with reduced activation of nuclear factor kappa B (NF-κB). These results indicate that preconditioning microglia with LPS induces a physiological immune tolerance response rather than pathological inflammation, which may have implications for developing therapeutic strategies for AD aimed at modulating innate immune memory.
    Keywords:  Alzheimer's disease; cytokines; immune tolerance; innate immune memory; microglia; neuroinflammation
    DOI:  https://doi.org/10.1111/jnc.70341
  3. J Neuroinflammation. 2025 Dec 30. 22(1): 303
      Microglial deformation and migration represent the final stages of inflammatory cytokines release, a key contributor to Alzheimer's disease (AD) pathology. However, the upstream regulators that initiate these morphological and functional changes in microglia remain unclear. In this study, we observed marked cytoskeletal reorganization in the hippocampal microglia of 2VO rats at 8 weeks, indicative of a shift from a homeostatic to a pro-inflammatory state. Notably, Tincr expression was significantly downregulated in both the microglia of 2VO rats and the hippocampi of AD patients. Tincr knockdown promoted microglial deformation and migration, accompanied by enhanced cytokines release and phagocytic capacity. These morphological changes correlated with redistribution of non-muscle myosin IIA ( NM IIA) and reduced expression of MYPT1, both in vitro and in vivo, effects that were reversed by Tincr overexpression. Genetic rescue of Mypt1 restored MYPT1 levels and attenuated Tincr-deficiency-induced microglial deformation in the hippocampi of 5xFAD mice. Mechanistically, Tincr enhanced MYPT1 protein expression through dual: functioning as a competing endogenous RNA (ceRNA) that sponged miR-153-3p, and serving as a direct protein-binding scaffold for MYPT1, thereby suppressing NM IIA phosphorylation and stabilizing microglial structure. These findings identify the Tincr-MYPT1-NM IIA axis as a critical regulatory pathway underlying chronic cerebral hypoperfusion (CCH)-induced microglial deformation and dysfunction, offering a novel mechanistic insight into the pathogenesis of neuroinflammation in AD.
    Keywords:   Tincr ; Chronic cerebral hypoperfusion; Cognitive impairment; MYPT1; Microglial cells deformation; NM IIA
    DOI:  https://doi.org/10.1186/s12974-025-03560-x
  4. Mol Neurobiol. 2025 Dec 29. 63(1): 335
      Monomeric C-reactive protein (mCRP) is a key acute phase reactant involved in inflammatory responses. Cerebral ischemia triggers persistent neuroinflammation. However, the effects of mCRP on global cerebral ischemia are poorly understood. In present study, mCRP was intracerebroventricularly injected to brain, and a bilateral common carotid artery ligation (BCAL) model was established in CX3CR1GFP/+ mice. Behavioral tests were employed to evaluate spontaneous activity, rotarod performance (latency to fall), and forelimb grasping strength in mice. Nissl and Fluoro-Jade C (FJ-C) staining were used to assess neuronal injury. Skeletonization analysis and CD16/32, CD206 staining were used to assess microglial activation. RT-qPCR was applied to evaluate the changes of inflammatory factors and complement system. Primary cultured microglia and oxygen-glucose deprivation (OGD) model were used to verify the effects of mCRP on microglia in vitro. Results showed that mCRP treatment exacerbated behavioral performance post-ischemia. Nissl staining showed that mCRP caused a significant decrease in neuronal density. Additionally, FJ-C staining indicated an increase in degenerative cells after mCRP treatment. Immunofluorescence analysis revealed an increase in CD16/32 and CD206-positive microglia, and skeletonization analysis showed increased de-ramification of microglia following mCRP administration. RT-qPCR results further demonstrated that mCRP treatment upregulated the expression of pro-inflammatory and anti-inflammatory factors, as well as complement system components, in both brain tissue and primary cultured microglia following ischemia or OGD. These findings suggest that mCRP significantly enhances microglial activation, increases the level of inflammatory response, exacerbates neuronal loss and degenerative damage, and impairs behavioral performance after ischemia.
    Keywords:  Global cerebral ischemia; Inflammation; MCRP; Microglia
    DOI:  https://doi.org/10.1007/s12035-025-05631-9
  5. Int J Mol Sci. 2025 Dec 17. pii: 12128. [Epub ahead of print]26(24):
      Alzheimer's disease (AD) is characterized by the accumulation and aggregation of tau and amyloid-β (Aβ). The pathophysiology and progression of AD are facilitated by the neurotoxic effects of these aggregated proteins, resulting in neurodegeneration and memory loss. In this context, the interaction between tau and Aβ42 is considered, but the mechanism underlying their pathogenic interplay remains unclear. Here, we addressed this question by studying the aggregation of full-length, unmodified tau and Aβ42 at physiologically low concentrations using atomic force microscopy (AFM). AFM imaging and data analyses demonstrate an increase in tau aggregation in the presence of Aβ42, characterized by increased sizes and number of aggregates. Importantly, tau aggregation occurs without the need for phosphorylation or any other post-translational changes. The analysis of the data demonstrates that tau and Aβ42 form co-aggregates, with no visible accumulation of Aβ42 aggregates alone. Given that the catalysis of tau aggregation by Aβ42 is observed at physiological low nanomolar concentrations of Aβ42, the finding suggests that such aggregation catalysis of tau by Aβ42 can be a molecular mechanism underlying the pathological tau aggregation process associated with the onset and development of Alzheimer's disease.
    Keywords:  AFM imaging; Alzheimer’s disease; aggregation; amyloid beta; tau
    DOI:  https://doi.org/10.3390/ijms262412128
  6. J Neurochem. 2025 Dec;169(12): e70334
      Microglia play a pivotal role in inflammatory regulation through multifarious signaling pathways within the central nervous system, and mitigating microglial inflammation is considered a promising strategy to delay the progression of neurodegeneration. However, the role of biased receptor signaling in modulating microglial inflammation remains largely unexplored. In this study, the anti-inflammatory effects and the underlying mechanism of muscarinic receptor agonists pilocarpine and iperoxo were explored. Our results showed that pilocarpine, rather than iperoxo, inhibited the expression of TNF-α and IL-6, as well as restored ramified morphology and physiological phagocytosis of over-activated microglia. RNA-seq revealed that pilocarpine-treated BV2 exhibited transcriptional profiles more similar to the control group, with upregulation of anti-inflammatory genes. β-arrestin2 knockdown attenuated the anti-inflammatory effect of pilocarpine by reversing the expression of inflammatory factors and activation of NF-κB. Furthermore, through chemogenetic DREADDs, activation of Gαq, Gαi, or β-arrestin pathways demonstrated that β-arrestin, but neither Gαq nor Gαi, inhibited the inflammatory response in microglia. Our findings proved that pilocarpine could abate the microglial inflammatory response via biased activation of the β-arrestin2 pathway, which could be considered a promising therapeutic approach for anti-neuroinflammation.
    Keywords:  microglia; muscarinic receptor; neuroinflammation; pilocarpine; signaling bias
    DOI:  https://doi.org/10.1111/jnc.70334
  7. Sci Immunol. 2026 Jan 02. 11(115): eadu4944
      Heart failure and ischemic heart disease represent prevalent causes of death among cancer survivors. Despite extensive use of conventional chemotherapies, a limited understanding of how these agents affect the cardiac immune landscape exists. Using mouse models, we show that DNA-damaging agents selectively deplete cardiac-resident macrophages through activation of p53 signaling and resultant necroptosis and apoptosis. Genetic lineage tracing, transcriptomic profiling, and functional studies revealed that recruited monocytes progressively reconstitute the cardiac-resident macrophage compartment, were transcriptionally distinct from embryonic-derived cardiac-resident macrophages, and conferred protection from subsequent hypertensive and ischemic cardiac injury in mice. Monocyte-derived resident-like cardiac macrophages suppressed inflammation and attenuated adverse myocardial remodeling through a type I interferon-dependent mechanism. Collectively, these findings highlight unrecognized effects of DNA-damaging chemotherapies on the cardiac immune landscape and shed light on our understanding of monocyte plasticity and resident macrophage dynamics.
    DOI:  https://doi.org/10.1126/sciimmunol.adu4944
  8. Mol Aspects Med. 2026 Jan 01. pii: S0098-2997(25)00108-6. [Epub ahead of print]107 101444
      Alzheimer's disease (AD) is increasingly recognized as a neuroinflammatory disorder driven by microglial dysfunction. The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway plays a critical role in neuroinflammation and has been strongly implicated in the pathology of AD. Chronic activation of cGAS-STING contributes to neurodegeneration by driving persistent type I interferon release and excessive pro-inflammatory cytokine production. However, the pathway exhibits context-dependent effects. Transient activation promotes antiviral defense, autophagy, and cellular quality control in the central nervous system. Sustained engagement exacerbates neuroinflammation and synaptic loss. Preclinical studies demonstrate that pharmacological inhibitors (such as NR, TSG, H-151, TDI-6750, TDI-8246) mitigate amyloid beta and tau pathology, attenuate microglial reactivity, and enhance cognitive outcomes. Yet, its essential physiological roles, including antimicrobial immunity and autophagy regulation, pose challenges for therapeutic targeting. This potentially disrupts neuroimmune homeostasis. In this review, we highlight the role of cGAS-STING in AD and explore its potential as a therapeutic target using small-molecule drug candidates. Despite these promising findings, challenges remain, including optimizing blood-brain barrier (BBB) penetration, ensuring immune specificity, and addressing long-term safety concerns. Due to these challenges, no cGAS-STING inhibitors have entered clinical trials for AD. However, the future of AD treatment may involve modulation of neuroinflammatory pathways, with cGAS-STING inhibitors playing a central role in reshaping neuroimmune homeostasis.
    Keywords:  Alzheimer's disease; Microglia; Mitochondrial dysfunction; Neuroinflammation; Small-molecule therapeutics; cGAS-STING signaling
    DOI:  https://doi.org/10.1016/j.mam.2025.101444
  9. Neurobiol Dis. 2025 Dec 25. pii: S0969-9961(25)00454-1. [Epub ahead of print] 107237
      Neuroinflammation is increasingly recognized as a central pathological mechanism in Parkinson's disease (PD), a progressive neurodegenerative disorder marked by dopaminergic neuron loss and diverse motor and non-motor symptoms. The NLRP3 inflammasome and its adaptor protein ASC are critical to initiating and sustaining inflammatory responses in the central nervous system. Although acute inflammasome activation supports host defence responses, chronic activation has been linked to the pathogenesis of PD. Increasing evidence indicates that mutations in the Leucine-Rich Repeat Kinase 2 (LRRK2), particularly the PD-associated G2019S mutation, enhance inflammatory signalling in microglia and peripheral immune cells. However, how LRRK2 intersects with the NLRP3 pathway remains unclear. Here, we investigate the role of LRRK2-G2019S in the priming and activation of the inflammasome in mouse primary microglia and human monocyte-derived microglia-like cells (hMDMi). Under unstimulated conditions, LRRK2-G2019S microglia displayed elevated NLRP3 expression and spontaneous formation of ASC specks within the nucleus, a subcellular localization not previously reported in microglia. Nuclear ASC specks also emerged in Wild Type microglia and hMDMi after lipopolysaccharide priming, but progressed to cytosolic ASC specks and IL-1β release only after canonical activation of NLRP3. These findings suggest that nuclear ASC specks mark a primed state of inflammasome activation in microglia. The LRRK2-G2019S mutation enhances this phenotype, potentially predisposing microglia to exaggerated inflammatory responses. This work identifies a novel cellular feature associated with PD-linked LRRK2 and uncovers a previously unrecognized layer of inflammasome regulation in microglia, offering new avenues to understand and target neuroinflammation in PD.
    Keywords:  ASC; Inflammasome; LRRK2; Microglia; NLRP3; Neuroinflammation; Parkinson's disease
    DOI:  https://doi.org/10.1016/j.nbd.2025.107237
  10. Sci Adv. 2026 Jan 02. 12(1): eaeb3991
      Autoimmune uveitis (AU) is a category of sight-threatening diseases with different pathological causes. Transcriptomic analysis of patients with AU revealed a highly oxidative stress profile as well as an up-regulated apolipoprotein E (APOE) expression in their peripheral blood mononuclear cells (PBMCs). In addition, single-cell RNA sequencing of retinal microglia also identified an up-regulated expression of APOE in a murine model of experimental AU (EAU). Our results and others previously suggested that microglia are tightly associated with the development of AU. Meanwhile, although APOE has been reported to play a myriad of functions ranging from lipid metabolism to neural regeneration, little is known about its detailed mechanism in the development of AU. In this study, a murine EAU model was used to investigate the association between APOE, microglia, and EAU, and it is found that APOE is indispensable for EAU induction as APOE-/- mice failed to develop EAU. In vitro studies using microglial cells further demonstrated that APOE is positively corelated with microglial inflammation, which could be reversed by knocking down APOE using short hairpin RNA. Proteomic analysis indicated that APOE-mediated microglial activation relies on reactive oxygen species (ROS) pathway, through peptidyl prolyl isomerase F (PPIF), which was further verified in PBMCs derived from patients with AU. Supplementation of PPIF reverses APOE deficiency-caused ROS activation in vitro. In addition, Adeno-associated virus-mediated overexpression of PPIF exacerbated EAU phenotype, suggesting its important role in driving uveitis initiation. These results provide an understanding of APOE and PPIF in the pathogenesis of uveitis.
    DOI:  https://doi.org/10.1126/sciadv.aeb3991
  11. J Neuroinflammation. 2025 Dec 30. 22(1): 302
      Brain border-associated macrophages (BAMs) are resident immune cells at the border of the central nervous system (CNS), and their physiological functions and roles in neurological diseases have been widely reported. However, the specific mechanisms by which BAMs contribute to vascular cognitive impairment and dementia (VCID) remain unclear. This article systematically reviews the subsets, origin and differentiation, molecular markers of BAMs, and their research progress in various brain diseases such as hypertension, Alzheimer's disease (AD), and stroke. On this basis, this article deeply analyzes the potential hypotheses of BAMs' involvement in the pathogenesis of VCID, including their regulation of neurovascular unit (NVU) homeostasis, their core role in neuroimmune inflammation, their impact on the lipid metabolism pathways in the CNS, and their involvement in the pathogenesis of vascular risk factor-related cognitive impairment (VRFCI). The mechanistic hypotheses proposed in this article aim to provide new perspectives for understanding the pathophysiology of VCID and may open up new directions for the development of early intervention and targeted treatment strategies.
    Keywords:  Border-associated macrophages; Brain diseases; Central nervous system; Subsets; Vascular cognitive impairment and dementia
    DOI:  https://doi.org/10.1186/s12974-025-03631-z
  12. Brain Behav Immun. 2025 Dec 29. pii: S0889-1591(25)00490-8. [Epub ahead of print] 106248
      Microglia are the primary immune cells of the central nervous system and maintain tissue homeostasis through phagocytosis and regulation of inflammatory signalling. Although these functions are well established, the molecular mechanisms that control microglial activation during neurodegeneration remain poorly understood. We focused on the Purkinje Cell Degeneration (PCD) mouse, which carries a loss-of-function mutation in Ccp1 that disrupts tubulin post-translational modifications essential for cytoskeletal stability. Because cytoskeletal dynamics are fundamental for microglial motility, phagocytosis, and proliferation, the Ccp1 mutation offers a model to directly examine how intrinsic cytoskeletal defects alter microglial behaviour and how these alterations manifest within regions undergoing distinct patterns of neurodegeneration. To this end, we combined in vitro and in vivo approaches. Microglia were isolated from neonatal cortex and adult cerebellum and olfactory bulb, and microglia-like cells were generated from bone marrow-derived hematopoietic stem cells. In vivo microglial depletion was achieved with the CSF1R inhibitor PLX5622. Immunohistochemistry quantified microglial density, morphology, and marker expression; transcriptomic profiling assessed identity and functional pathways; and functional assays evaluated phagocytosis, motility, and proliferation. Motor behaviour tests were performed to determine whether microglial dysfunction contributes to circuit-level impairments. Statistical analyses used parametric or non-parametric tests according to distribution. Ccp1-deficient microglia exhibited intrinsic deficits in phagocytosis, motility, and proliferation, independent of overt neuronal loss. These impairments were amplified in degenerating regions, where microglia adopted a predominantly anti-inflammatory rather than pro-inflammatory activation profile. This atypical state suggests a maladaptive response that may compromise tissue homeostasis and intensify disease progression. Consistent with this, animals showed altered motor behaviour, indicating functional consequences of microglial dysfunction. Together, these findings identify Ccp1 as a key regulator of microglial homeostasis and demonstrate how cytoskeletal disruption can reshape microglial responses in neurodegenerative environments, providing mechanistic insight and potential therapeutic targets.
    Keywords:  Cytoskeleton; Immune response; Microglia; Microgliosis; Motor behaviour; Neurodegeneration; Neuroinflammation
    DOI:  https://doi.org/10.1016/j.bbi.2025.106248
  13. Mol Neurobiol. 2025 Dec 29. 63(1): 336
      Alzheimer's disease (AD) is a common neurodegenerative disease of the elderly and the sixth leading cause of death. Various risk factors are responsible for the disease, including aging, vascular disorders, head trauma, infection, genetics, and environmental conditions. Amyloid beta (Aβ) and neurofibrillary tangle (NFT) build-up lead to the generation of free radicals, which in turn cause oxidative stress and neuroinflammation that further cause synaptic and mitochondrial dysfunction. These inflammatory responses primarily stem from the overactivation of microglial and astroglial cells, producing cytokines and chemokines. However, immune cell migration has also been observed in the central nervous system (CNS) via blood-brain barrier (BBB) disruption, in which neutrophils have grabbed more attention due to their migration and formation of neutrophil extracellular traps (NETs) in AD brain parenchyma and blood vessels, causing chronic neuroinflammation and neuronal damage via NETosis. NETosis is the immune system's defense mechanism in which neutrophils form web-like structures to trap pathogens and digest them with their antimicrobial and cytotoxic peptides and release inflammatory cytokines. Neutrophils and NETs have been observed in many studies surrounding Aβ plaques in the brain parenchyma and cerebral blood vessels, causing neuronal tissue damage and AD progression. The ongoing research advocates that by targeting conventional Aβ plaques and tau build-up, managing neuroinflammation, particularly caused by NETosis, may delay the onset or reduce its progression. In the growing health care scenario, to avoid any side effects and the cost of the present discovered drugs, the focus should be on organic or natural components/compounds for which phytochemicals will be the best to target NETosis, as they have many medicinal properties like anti-oxidant, anti-inflammatory, anti-microbial, and immunomodulatory. This review focuses on understanding the molecular association between neuroinflammation in NETs and AD progression and the role of plant-derived constituents in tackling the NETosis-induced AD progression.
    Keywords:  Alzheimer’s disease; Neuroinflammation; Neutrophil extracellular traps; Neutrophils; Phytochemicals
    DOI:  https://doi.org/10.1007/s12035-025-05435-x
  14. Brain Behav Immun. 2025 Dec 25. pii: S0889-1591(25)00488-X. [Epub ahead of print]133 106246
      Early-life adversity (ELA) is a significant risk factor for emotional disorders like depression, likely due to changes in stress-related circuit development. We have previously shown that ELA increases the number of excitatory synapses onto corticotropin-releasing hormone (CRH)-expressing neurons in the paraventricular nucleus (PVN) by decreasing microglial synapse engulfment. Here, we hypothesize that ELA induces microglial dysfunction via inhibition of the microglial phagocytic receptor, MerTK, thus resulting in the observed changes in synapses and stress-related behavior. To determine whether deleting MerTK in microglia phenocopies the effects of ELA, microglia-specific conditional knockout (m)MerTK-KO (CX3CR1-Cre+::MerTKfl/fl) mice were crossed with 'wild-type' (CX3CR1-Cre-::MerTKfl/fl) mice, and their litters were reared in either a control or ELA (induced by limited bedding and nesting) environment, from postnatal days (P)2-10. Excitatory synapses in the PVN were assessed at P10, microglial engulfment was assessed at P8, and adult offspring were tested in a behavioral battery to measure threat-response (known to be dependent on PVN-CRH+ neurons) and anxiety-like behavior, followed by acute restraint stress to measure the neuroendocrine stress response. Following ELA at P10, we find that excitatory, but not inhibitory, synapses in the PVN are increased in males, which is mimicked by mMerTK-KO in control males, but causes no further increase in ELA males. Correspondingly, ELA and mMerTK-KO decrease microglial engulfment of excitatory presynaptic terminals at P8 in males. In contrast, females already have higher numbers of excitatory synapses at baseline, and exhibit no further increase with ELA or mMerTK-KO. Remarkably, the pattern of threat-response behavior in males closely matches the excitatory synapses, with mMerTK-KO control males escaping more from the simulated predator threat in the looming-shadow threat task, similar to ELA males. Again, females do not show any significant changes due to ELA or mMerTK-KO in the threat-response, although they do exhibit ELA-induced changes in anxiety-like behavior. ELA provokes a greater corticosterone response to acute stress in males, but not females, although females were again already higher at baseline. In sum, our results demonstrate that ELA provokes decreased microglial engulfment during development, leading to increased excitatory synapses in the PVN and an increased active response to threat in the looming-shadow test in males only. Deleting MerTK specifically from microglia recapitulates both the synaptic and behavioral effects in control males, but does not have an effect in ELA males or control females, suggesting that the MerTK pathway is already inhibited by ELA in males and less active in females at baseline. Our work is the first to elucidate the mechanisms underlying the male-biased microglial dysfunction caused by ELA, with promise for the development of better preventative and therapeutic strategies for at-risk children.
    Keywords:  CRH+ neurons; Early-life adversity; MerTK; Microglia; PVN; Stress; Synaptic pruning; Threat response
    DOI:  https://doi.org/10.1016/j.bbi.2025.106246
  15. J Neuroinflammation. 2025 Dec 30. 22(1): 304
      Traumatic brain injury (TBI) frequently causes cognitive dysfunction, with astrocytes playing a pivotal role in its pathogenesis. ​Specifically,​​ TBI triggers excessive astrocyte reactivity, ​leading to a phagocytic phenotype in astrocytes that contributes to abnormal synaptic phagocytosis and cognitive decline. ​Sirtuin 1 (SIRT1) reduction was region-specific, with significant downregulation observed in the hippocampus and cortex, reflecting the selective vulnerability of these regions to TBI-induced pathology. Although​ SIRT1 ​is​ a neuroprotective deacetylase, its regulatory mechanism in post-TBI astrocyte phagocytosis remains unclear. This study elucidates the mechanism through which SIRT1 attenuates TBI-induced cognitive deficits, specifically by ​​promoting autophagic flux in astrocytes​​ and subsequently ​​suppressing MEGF10-mediated synaptic phagocytosis​​. The investigation leveraged a combination of clinical human samples and astrocyte-specific murine models, including SIRT1-overexpression and ATG7-knockdown systems. Crucially, ​​astrocyte-specific knockdown of ATG7​​ was employed to mechanistically demonstrate that the SIRT1-driven degradation of MEGF10 and the consequent synaptic preservation are ​​strictly dependent on a functional autophagy pathway​​, as evidenced by the complete abolition of SIRT1's beneficial effects upon ATG7 knockdown. ​Methodologies included​ Western blotting, immunofluorescence, behavioral tests (Barnes maze), and in vitro assays. Notably, TBI ​significantly​ reduced SIRT1 levels; astrocytic SIRT1 overexpression ​suppressed​ MEGF10 expression via ATG7-dependent autophagy, ​thereby​ alleviating astrogliosis, synaptic loss, and cognitive deficits. ​Critically, these protective effects were abrogated by​ ATG7 knockdown. ​Collectively, our results define​ the SIRT1-autophagy-MEGF10 axis ​as a key regulator​ of astrocytic phagocytosis, ​revealing​ a novel therapeutic target for injury-related cognitive dysfunction.
    Keywords:  Astrocytic phagocytosis; Cognitive deficits; Traumatic brain injury
    DOI:  https://doi.org/10.1186/s12974-025-03633-x
  16. Adv Sci (Weinh). 2025 Dec 29. e15138
      Persistent microglial activation drives chronic neuroinflammation, a characteristic pathological hallmark of neurodegenerative disorders, including Parkinson's disease (PD). Although integrin receptor CD49a (Itga1 gene) serves as a canonical biomarker of tissue-resident immune populations, its microglial expression patterns, functions, and signaling pathways have not been elucidated. In this study, we aim to investigate the impact of CD49a in hyperactivated microglia on PD pathogenesis and elucidate downstream signaling pathways. Specifically, we demonstrate microglia-enriched CD49a expression with pathologically significant upregulation particularly in microglia adopting chronically activated states. Specific Itga1 knockdown attenuates microglial hyperreactivity and markedly improves motor deficits in PD mouse models. Mechanistically, transcriptomic profiling of isolated microglia from mouse substantia nigra reveals significant enrichment in neurodegeneration and inflammation pathways, with PGAM5 emerging as a central regulatory node. Conditional microglial Itga1 knockdown ameliorates mitochondrial dysfunction and suppresses NLRP3 inflammasome assembly via PGAM5 downregulation, thereby preserving dopaminergic neurons from neuroinflammatory degeneration. Furthermore, the disintegrin polypeptide obtustatin specifically antagonizes microglial CD49a, suppressing microglial hyperactivation and consequent chronic neuroinflammation, and ultimately ameliorating motor deficits in PD models. Collectively, these findings establish microglial CD49a-targeted therapy as a novel therapeutic paradigm for PD, positioning obtustatin as a promising clinical candidate with demonstrable translational potential across neuroinflammatory and neurodegenerative disorders.
    Keywords:  CD49a; Parkinson's disease; integrin; microglia; neuroinflammation; peptide
    DOI:  https://doi.org/10.1002/advs.202515138
  17. Mol Biomed. 2025 Dec 29. 6(1): 153
      The receptor for triggering expressed on myeloid cells 2 (Trem2), which is a key hub of immune signals, is a cell-surface receptor expressed selectively in myeloid cells. Macrophages have multi-faceted functions in vascular aging. However, the function of Trem2 and its ligands in vascular aging has not been described. Here, we investigated Trem2's function in aging vasculature using transcriptome analysis, western blotting, and quantitative polymerase chain reaction (qPCR) to assess its expression. Aged (24-month-old) wild-type mice exhibited significantly upregulated Trem2 in aortic senescent macrophages compared to young (2-month-old) controls. Compared with littermate controls, aged mice with macrophage-specific Trem2 knockout (T2-cKO) developed exacerbated arterial stiffness, impaired vascular contractility, and an acceleration of histological aging markers. Trem2 deficiency intensified aortic inflammatory responses and oxidative stress. Mechanistically, interleukin (IL)-13 from senescent macrophages directly bound Trem2, activating the Syk-Sp1-SLC25A51 pathway to enhance mitochondrial nicotinamide adenine dinucleotide (NAD)⁺ transport. This triggered metabolic reprogramming, increasing alpha-ketoglutarate (α-KG) production, which modulated vascular smooth muscle cell (VSMC) phenotype. Notably, α-KG supplementation in vivo rescued Trem2 deficiency-driven vascular aging and dysfunction. Our study identifies the IL-13/Trem2 axis as a protective mechanism against vascular aging via α-KG-dependent metabolic crosstalk between macrophages and VSMCs. Thus, Trem2 may be a treatment target for diseases related to vascular aging.
    Keywords:  IL-13; Macrophage; Metabolic reprogramming; Trem2; Vascular aging; α-KG
    DOI:  https://doi.org/10.1186/s43556-025-00377-1
  18. iScience. 2025 Dec 19. 28(12): 114217
      Aging and accumulation of α-synuclein (α-syn) oligomers in the brain are indisputably linked to Parkinson's disease (PD). Using an inducible α-syn oligomer mouse model, we demonstrate that the induction of PD-associated α-syn oligomers for the same time span caused PD-associated symptoms only in aged, but not in young mice. Biochemical studies revealed that α-syn oligomer formation precedes motor decline, with age and α-syn expression jointly determining the motor phenotype. Single-nucleus RNA sequencing (snRNA-seq) identified a PD-related transcriptional signature in basal ganglia neurons (BGNs), which overlapped in part with aging-associated changes. Short-term pharmacological inhibition of the small RhoGTPase CDC42 in aged, symptomatic animals improved motor function without reducing oligomer levels. These findings indicate that aging processes strongly influence the susceptibility to PD-like symptoms and that targeting age-related pathways, rather than α-syn oligomer burden alone, may provide effective strategies to improve outcomes in PD.
    Keywords:  Model organism; Molecular biology; Neuroscience; Transcriptomics
    DOI:  https://doi.org/10.1016/j.isci.2025.114217
  19. Proc Natl Acad Sci U S A. 2026 Jan 06. 123(1): e2511401122
      For reasons not fully understood, proresolving immune processes sometimes fail to engage after peripheral nerve injury (PNI), leading to enhanced neuropathic pain and inflammation. Here, we implicate reduced efferocytosis due to proteolytic cleavage of surface MER tyrosine kinase (MERTK) from macrophages at the site of PNI. After PNI, the proportion of macrophages expressing MERTK progressively decreased, while soluble (cleaved) MER increased. Using male and female knock-in mice encoding cleavage-resistant Mertk, we demonstrated that cleavage of MERTK from macrophages at the PNI site led to exaggerated pain-related behaviors. PNI-induced hyperactivity of TRPV1+ sensory neurons and damage to myelin and myelinated axons was exacerbated by MERTK cleavage. Cleavage of MERTK led macrophages to adopt a proinflammatory phenotype. It also reduced their efferocytotic capacity, increasing accumulation of TUNEL+ (apoptotic) and RIPK3+ (necroptotic) cells at the injury site. The pronociceptive damage-associated molecular patterns (DAMPs) interleukin-33 and heat shock protein-90 were increased, consistent with passive release from uncleared cell corpses. These corpses can also release de novo antigens along with DAMPs to trigger autoimmunity, recently implicated in neuropathic pain through a mechanism involving secretion of immunoglobulin G (IgG). Indeed, MERTK cleavage led to accumulation of IgG at the injury site and dorsal root ganglia. All outcomes were further worsened when Mertk was conditionally deleted from macrophages. Our findings identify cleavage of MERTK from macrophages at the injury site as a pivotal regulator of pronociceptive and tissue-damaging neuroimmune signaling after PNI.
    Keywords:  ADAM17; TAM receptors; efferocytosis; pain; autoimmunity
    DOI:  https://doi.org/10.1073/pnas.2511401122